Literature DB >> 21149667

Exacerbation of cerebral radiation necrosis by bevacizumab.

Deva Sanjeeva Jeyaretna1, William T Curry, Tracy T Batchelor, Anat Stemmer-Rachamimov, Scott R Plotkin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21149667     DOI： 10.1200/JCO.2010.31.4815

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  34 in total

1.  In search of a treatment for radiation-induced optic neuropathy.

Authors:  Maanasa Indaram; Ferhina S Ali; Marc H Levin
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

2.  Preclinical MRI: Studies of the irradiated brain.

Authors:  Joel R Garbow; Christina I Tsien; Scott C Beeman
Journal:  J Magn Reson       Date:  2018-04-26       Impact factor: 2.229

3.  Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab.

Authors:  N Bahrami; D Piccioni; R Karunamuni; Y-H Chang; N White; R Delfanti; T M Seibert; J A Hattangadi-Gluth; A Dale; N Farid; C R McDonald
Journal:  AJNR Am J Neuroradiol       Date:  2018-04-05       Impact factor: 3.825

4.  Can anti-vascular endothelial growth factor antibody reverse radiation necrosis? A preclinical investigation.

Authors:  Chong Duan; Carlos J Perez-Torres; Liya Yuan; John A Engelbach; Scott C Beeman; Christina I Tsien; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Joel R Garbow
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

5.  Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.

Authors:  H S Nguyen; N Milbach; S L Hurrell; E Cochran; J Connelly; J A Bovi; C J Schultz; W M Mueller; S D Rand; K M Schmainda; P S LaViolette
Journal:  AJNR Am J Neuroradiol       Date:  2016-08-04       Impact factor: 3.825

6.  An analysis of radiation necrosis of the central nervous system treated with bevacizumab.

Authors:  Karen Tye; Herbert H Engelhard; Konstantin V Slavin; M Kelly Nicholas; Steven J Chmura; Young Kwok; Dominic S Ho; Ralph R Weichselbaum; Matthew Koshy
Journal:  J Neurooncol       Date:  2014-02-07       Impact factor: 4.130

Review 7.  Delayed brain radiation necrosis: pathological review and new molecular targets for treatment.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Shinji Kawabata; Shin-Ichi Miyatake; Toshihiko Kuroiwa
Journal:  Med Mol Morphol       Date:  2015-12       Impact factor: 2.309

8.  Results of a questionnaire regarding practice patterns for the diagnosis and treatment of intracranial radiation necrosis after SRS.

Authors:  Abigail L Stockham; Manmeet Ahluwalia; Chandana A Reddy; John H Suh; Aryavarta Kumar; Michael A Vogelbaum; Gene H Barnett; Erin S Murphy; Samuel T Chao
Journal:  J Neurooncol       Date:  2013-09-18       Impact factor: 4.130

9.  Diffusion abnormalities of the corpus callosum in patients receiving bevacizumab for malignant brain tumors: suspected treatment toxicity.

Authors:  Stephen F Futterer; Alexander J Nemeth; Sean A Grimm; Ann B Ragin; James P Chandler; Kenji Muro; Maryanne H Marymont; Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2014-02-28       Impact factor: 4.130

10.  A GSK-3β inhibitor protects against radiation necrosis in mouse brain.

Authors:  Xiaoyu Jiang; Carlos J Perez-Torres; Dinesh Thotala; John A Engelbach; Liya Yuan; Jeremy Cates; Feng Gao; Robert E Drzymala; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Dennis E Hallahan; Joel R Garbow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.